William Blair Weighs in on Exagen's Q1 Earnings (NASDAQ:XGN)

Exagen Inc. (NASDAQ:XGN - Free Report) - Stock analysts at William Blair increased their Q1 2025 earnings per share estimates for shares of Exagen in a research note issued on Wednesday, March 12th. William Blair analyst A. Brackmann now forecasts that the company will earn ($0.20) per share for the quarter, up from their previous estimate of ($0.24). William Blair has a "Outperform" rating on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen's Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.55) EPS.

Several other equities analysts have also recently issued reports on XGN. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price objective on shares of Exagen in a research report on Monday, January 13th. Canaccord Genuity Group upped their price objective on Exagen from $5.00 to $7.00 and gave the company a "buy" rating in a research report on Friday, January 3rd.

Exagen Stock Performance

XGN stock remained flat at $3.62 during midday trading on Friday. The company had a trading volume of 40,498 shares, compared to its average volume of 81,552. The stock has a market capitalization of $64.79 million, a P/E ratio of -3.85 and a beta of 1.40. Exagen has a fifty-two week low of $1.30 and a fifty-two week high of $6.22. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The business has a 50 day simple moving average of $3.78 and a 200-day simple moving average of $3.58.

Remove Ads

Institutional Investors Weigh In On Exagen

Several hedge funds and other institutional investors have recently modified their holdings of XGN. Toronto Dominion Bank purchased a new stake in shares of Exagen in the 4th quarter worth $3,655,000. Driehaus Capital Management LLC purchased a new stake in shares of Exagen in the 4th quarter worth $1,716,000. Stonepine Capital Management LLC increased its stake in shares of Exagen by 49.0% in the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company's stock worth $1,651,000 after purchasing an additional 175,701 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Exagen in the 4th quarter worth $66,000. Finally, Kennedy Capital Management LLC increased its stake in shares of Exagen by 8.8% in the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company's stock worth $756,000 after purchasing an additional 14,920 shares in the last quarter. 75.25% of the stock is currently owned by hedge funds and other institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).